MYOS RENS Technology Inc. (NASDAQ:MYOS) issued its earnings results on Tuesday. The company reported ($0.13) earnings per share for the quarter, Bloomberg Earnings reports. MYOS RENS Technology had a negative return on equity of 71.09% and a negative net margin of 940.66%.

Shares of MYOS RENS Technology (NASDAQ MYOS) traded up $0.17 on Wednesday, reaching $1.33. 862,000 shares of the company were exchanged, compared to its average volume of 610,805. MYOS RENS Technology has a fifty-two week low of $1.02 and a fifty-two week high of $6.98.

COPYRIGHT VIOLATION WARNING: This story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this story on another website, it was copied illegally and republished in violation of US & international copyright law. The original version of this story can be read at

Separately, ValuEngine upgraded shares of MYOS RENS Technology from a “strong sell” rating to a “sell” rating in a report on Wednesday, September 6th.

MYOS RENS Technology Company Profile

MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.

Receive News & Stock Ratings for MYOS RENS Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology Inc. and related stocks with our FREE daily email newsletter.